AC Immune

ACIU

Lausanne, Switzerland· Est. 2003

acimmune.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

ACIU · Stock Price

USD 2.92+1.24 (+73.81%)

Market Cap: $293.1M

Historical price data

Market Cap: $293.1MPipeline: 7 drugsFounded: 2003Employees: ~150HQ: Lausanne, Switzerland

Sector Ranking#44 in Neuroscience & CNS #145 in Biologics / Biosimilars

Overview

AC Immune's mission is to diagnose, treat, and prevent neurodegenerative diseases through a precision medicine approach. The company has achieved significant validation through high-value partnerships with major pharmaceutical firms like Takeda, Janssen, and Lilly, and its pipeline features promising Phase 2 candidates in Alzheimer's and Parkinson's disease. Its strategy balances internal R&D of first- and best-in-class candidates with strategic collaborations that provide non-dilutive funding and de-risk development.

Alzheimer's DiseaseParkinson's DiseaseNeurodegenerative Diseases

Technology Platform

Two proprietary platforms: SupraAntigen® for designing best-in-class active immunotherapies and antibodies, and Morphomer® for discovering orally available, brain-penetrant small molecules that inhibit pathological protein aggregation.

Pipeline

7 drugs in pipeline

Drug	Indication	Stage
ACI-24 + Placebo	Down Syndrome	Phase 2
Placebo + ACI-7104.056 at Dose A + ACI-7104.056 at Dose B (o...	Parkinson Disease	Phase 2
Placebo + ACI-24.060 at Dose A + ACI-24.060 at Dose B + ACI-...	Amyloid Plaque	Phase 1/2
ACI-35.030 + ACI-35.030 + ACI-35.030 + JACI-35.054 + JACI-35...	Alzheimer's Disease	Phase 1/2
ACI-24 low dose + ACI-24 high dose + Placebo	Down Syndrome	Phase 1

Funding History

Total raised:$125M

PIPE$50MUndisclosedJun 15, 2020

IPO$60MUndisclosedSep 30, 2016

Series A$15MUndisclosedJun 15, 2003

Opportunities

The recent validation of the amyloid hypothesis creates a multi-billion dollar market for next-generation, safer, and more convenient disease-modifying therapies.

AC Immune is poised to capture value with its diversified pipeline targeting amyloid, Tau, and alpha-synuclein, including a potentially first-in-class Parkinson's vaccine and critical diagnostic tools for patient stratification.

Risk Factors

High clinical failure risk inherent in neurodegenerative drug development; finite cash runway requiring future dilutive financing; intense competition from large pharma with greater resources; and reliance on partners for key programs, ceding control and economic upside.

Competitive Landscape

Competes with large-cap biopharma (Lilly, Roche, Biogen) in Alzheimer's and a smaller set of biotechs in Parkinson's. Key differentiators are its dual technology platforms enabling multiple therapeutic modalities and its strong, validating partnership network with major pharmaceutical companies.